Page 41 - GTM-2-4

Global Translational Medicine The research advances in HPV integration

References [129,130] https://clinicaltrials.gov/study/ NCT04646005 [131] [132] [133] [134] [135] [136]

Status Phase II completed Phase II Phase I/II Phase I/II completed Phase II ongoing Phase II recruiting Phase II ongoing Phase II recruiting

Treatment effect This treatment gave a promising response rate of 33% and remains promising in long-term follow-up N/A PRGN-2009 treatment reduced tumor volume and increased CD8 + and CD4 + T cell levels in the tumor microenvironment of humanized mice bearing the human cervical tumor The objective response rate was 27.6%. However, 28 (80.0%) patients had treatment-related adverse events At 24 weeks, 11 (42%) of 26 patients achieved an ov

ISA101 is a synthetic long-peptide anti-HPV16 vaccine covering the complete sequence of E6 and E7; nivolumab is used for PD-1 immune checkpoint blockade Cemiplimab is an anti-PD-1 monoclonal antibody PRGN-2009 is a therapeutic gorilla adenovirus vaccine containing multiple cytotoxic T cell epitopes from the viral oncoproteins HPV16/18 E6 and E7; M7842 is an anti-PD-L1/ TGF-β trap fusion protein MEDI0457 is a DNA vaccine targetin

Principle fusion proteins

ISA101 and nivolumab ISA101 and cemiplimab PRGN-2009 alone or in combination with M7824 MEDI0457 plus pembrolizumab GX-188E, GX-I7 and pembrolizumab VB10.16 and atezolizumab pBI-11 and TA-HPV

Name durvalumab GX-188E and

Cancer type HPV16+solid tumors HPV16+cervical cancer HPV positive cancers HPV-associated recurrent/ metastatic head-and-neck cancer HPV16- or HPV18- positive cervical cancer HPV16- and/or HPV18- positive head-and-neck cancer HPV16- positive cervical cancer PD-L1- and HPV- positive oropharyngeal cancer Abbreviation: ORR: Overall response rate
Table 2. (Continued) Clinical trial No. NCT02426892 NCT04646005 NCT04432597 NCT03162224 NCT03444376 NCT05286060 NCT04405349 NCT05799144

Volume 2 Issue 4 (2023) 15 https://doi.org/10.36922/gtm.2034